2-Chlorodeoxyadenosine (2-CdA) in 2-Hour Versus 24-Hour Intravenous Infusion in the Treatment of Patients with Hairy Cell Leukemia
Autor: | M. Kazimierczak, S. Kotlarek-Haus, Tadeusz Robak, L Usnarska-Zubkiewicz, Andrzej Hellmann, Z. Kuratowska, Barbara Zdziarska, M Błasińska-Morawiec, Paweł Grieb, Jadwiga Dwilewicz-Trojaczek, Jan Maciej Zaucha, E. Krykowski, J. Hołowiecki, L Urasiński, J. Hansz, M. Krawczyk-Kulis, Stanisław Maj, M Komarnicki, Lech Konopka |
---|---|
Rok vydání: | 1996 |
Předmět: |
Adult
Male Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty medicine.medical_treatment Splenectomy Alpha interferon Infections Disease-Free Survival medicine Chlorodeoxyadenosine Humans Immunologic Factors Hairy cell leukemia Infusions Intravenous Cladribine Aged Leukemia Hairy Cell business.industry Remission Induction Complete remission Interferon-alpha Hematology Intravenous Infusions Middle Aged medicine.disease Combined Modality Therapy Surgery Leukemia Treatment Outcome Oncology Anesthesia Female business medicine.drug |
Zdroj: | Leukemia & Lymphoma. 22:107-111 |
ISSN: | 1029-2403 1042-8194 |
DOI: | 10.3109/10428199609051736 |
Popis: | Forty one patients with hairy cell leukemia (HCL) were treated with 2-chloro-deoxyadenosine (2-CdA) administered in various schedules. Complete remission (CR) was achieved in 31 (76%) patients and partial remission (PR) in 9 (22%). The mean duration of remission (CR + PR) was 25.2 months (range 9-45 months). One patient did not respond to therapy. Twelve out of 16 patients (75%) achieved CR after 5-day intravenous infusions of 2-CdA and 19 out of 25 patients (76%) after 7-day courses. In 19 out of 23 patients (82.6%) CR was achieved after intermittent 2-hour infusions and in 12 out of 18 (66.7%) after continuous 24-hour infusion. The differences were not statistically significant. Side effects of 2-CdA were similar in both groups except for infections, which were less frequently observed in the group treated for 5 days. The results of our study suggest that 2-CdA can be effectively administered to patients with HCL using 5-day courses and a 2-hour daily infusion. |
Databáze: | OpenAIRE |
Externí odkaz: |